Skip to main content

CORRECTION article

Front. Physiol., 06 March 2023
Sec. Cell Physiology
Volume 14 - 2023 | https://doi.org/10.3389/fphys.2023.1163389
This article is part of the Research Topic Advances in cAMP signaling research: basic and translational aspects View all 7 articles

Corrigendum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential

This article is a correction to:

  1. Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential

    1. Read original article
Thomas RossettiThomas Rossetti1Jacob FerreiraJacob Ferreira1Lubna GhanemLubna Ghanem1Hannes BuckHannes Buck1Clemens SteegbornClemens Steegborn2Robert W. MyersRobert W. Myers3Peter T. MeinkePeter T. Meinke3Lonny R. Levin Lonny R. Levin1*Jochen BuckJochen Buck1
  • 1Department of Pharmacology, Weill Cornell Medicine, New York, NY, United States
  • 2Department of Biochemistry, University of Bayreuth, Bayreuth, Germany
  • 3Tri-Institutional Therapeutics Discovery Institute, New York, NY, United States

A Corrigendum on
Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential

by Rossetti T, Ferreira J, Ghanem L, Buck H, Steegborn C, Myers RW, Meinke PT, Levin LR and Buck J (2022). Front. Physiol. 13:1013845. doi: 10.3389/fphys.2022.1013845

In the original article, there was an error in Table 1 as published. In this table, the chemical structures of TDI-11861 and TDI-11155 were incorrect as the chloro and amino groups of the pyrimidine were drawn in the incorrect positions. In the correct chemical structures, the chloro and amino groups are located at the 4- and 2-positions, respectively. The corrected Table 1 appears below.

TABLE 1
www.frontiersin.org

TABLE 1. In Vitro Biochemical and Cellular Potency of sAC Inhibitors.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: soluble adenylyl cyclase, male contraceptive, residence time, drug development, picomolar potency, binding kinetics, lead optimization, SPR

Citation: Rossetti T, Ferreira J, Ghanem L, Buck H, Steegborn C, Myers RW, Meinke PT, Levin LR and Buck J (2023) Corrigendum: Assessing potency and binding kinetics of soluble adenylyl cyclase (sAC) inhibitors to maximize therapeutic potential. Front. Physiol. 14:1163389. doi: 10.3389/fphys.2023.1163389

Received: 10 February 2023; Accepted: 21 February 2023;
Published: 06 March 2023.

Edited and reviewed by:

Muhammad Aslam, University of Giessen, Germany

Copyright © 2023 Rossetti, Ferreira, Ghanem, Buck, Steegborn, Myers, Meinke, Levin and Buck. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Lonny R. Levin, llevin@med.cornell.edu

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.